UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1356-1384

2022

Volltextzugriff (PDF)

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Cell reports (Cambridge), 2015-04, Vol.11 (1), p.98-110

2015

Volltextzugriff (PDF)

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1718-1732

2021

Volltextzugriff (PDF)

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors

Clinical cancer research, 2014-12, Vol.20 (24), p.6295-6303

2014

Volltextzugriff (PDF)

Immunotherapies for Lung Cancer

Journal of the National Comprehensive Cancer Network, 2017-05, Vol.15 (5S), p.692

Gubens, Matthew A

2017

Volltextzugriff (PDF)

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer

Clinical cancer research, 2021-09, Vol.27 (18), p.5131-5140

2021

Volltextzugriff (PDF)

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Lung cancer (Amsterdam, Netherlands), 2019-04, Vol.130, p.59-66

2019

Volltextzugriff (PDF)

Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study

Pancreas, 2018-09, Vol.47 (8), p.958-966

2018

Volltextzugriff (PDF)

Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors

Endocrine-related cancer, 2024-01, Vol.31 (1)

2024

Volltextzugriff (PDF)

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

Lung cancer (Amsterdam, Netherlands), 2018-11, Vol.125, p.273-281

2018

Volltextzugriff (PDF)

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023

Journal of the National Comprehensive Cancer Network, 2023-04, Vol.21 (4), p.340

2023

Volltextzugriff (PDF)

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.793-801

2019

Volltextzugriff (PDF)

Long-Term Survivors of Gastric Cancer: A California Population-Based Study

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3507-3515

2012

Volltextzugriff (PDF)

Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study

Journal of the American Geriatrics Society (JAGS), 2022-01, Vol.70 (1), p.136-149

2022

Volltextzugriff (PDF)

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Nature communications, 2024-03, Vol.15 (1), p.2568-10, Article 2568

2024

Volltextzugriff (PDF)

Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1223-1232

2019

Volltextzugriff (PDF)

Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small cell lung cancer

Clinical lung cancer, 2018-01, Vol.19 (1), p.58-64

2018

Volltextzugriff (PDF)

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution

Scientific reports, 2017-03, Vol.7 (1), p.44206-44206, Article 44206

2017

Volltextzugriff (PDF)

Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era

Clinical lung cancer, 2014-05, Vol.15 (3), p.202-206

2014

Volltextzugriff (PDF)

Non-Small Cell Lung Cancer, Version 4.2024

Journal of the National Comprehensive Cancer Network, 2024-05, Vol.22 (4), p.249

2024

Volltextzugriff (PDF)

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies

Lung cancer (Amsterdam, Netherlands), 2015-07, Vol.89 (1), p.57-60

2015

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(92)

Sprache

Englisch
(91)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(43)
Humans
(41)
Oncology
(31)
Male
(24)
Female
(22)
Aged
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Lung Neoplasms - Drug Therapy
(16)
Middle Aged
(15)
Lung Neoplasms - Pathology
(14)
Respiratory System
(14)
Lung Cancer
(13)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(10)
Carcinoma, Non-Small-Cell Lung - Pathology
(10)
Chemotherapy
(10)
Adult
(9)
Aged, 80 And Over
(9)
Lung Neoplasms - Therapy
(9)
Neoplasm Staging
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors

Immunotherapies for Lung Cancer

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study

Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

Long-Term Survivors of Gastric Cancer: A California Population-Based Study

Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging

Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small cell lung cancer

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution

Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era

Non-Small Cell Lung Cancer, Version 4.2024

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies

Suchergebnisse filtern